Overview
- Australia’s immunisation advisory remains active, cautioning that counterfeit Abhayrab may have been given in India since November 1, 2023 and advising replacement doses for potentially affected recipients.
- Indian Immunologicals Limited says the issue was an isolated counterfeit tied to batch KA 24014, detected through a packaging anomaly in January 2025 and traced with regulators and law enforcement.
- The manufacturer states the suspect batch is no longer available for sale and requests Australian authorities to review and update the advisory language.
- IIL underscores that Indian-made vaccine batches are tested and released by the Central Drugs Laboratory, with supplies through government and authorised distributors described as safe.
- Indian coverage notes raids and seizures in multiple cities and reports similar alerts from the UK and US, while IIL highlights long-standing production with over 210 million Abhayrab doses and a 40% domestic market share.